Enroll in a study to learn how Alabama community pharmacists can save lives with naloxone
Why this Study?
Opioid abuse is a major public health issue in the United States. Over 250 million prescriptions for opioid pain relievers were written in the U.S. in 2012, and almost two million people were non-medically dependent on these medications in 2014. Indeed, prescription methadone, hydrocodone, and oxycodone are commonly implicated in medication-related fatalities. Nearly 22,000 people in the U.S. die annually due to prescription opioid overdose, as many as 62 people daily. The state of Alabama is of particular concern, as it has the highest rate of opioid prescribing in the U.S., and drug overdose deaths increased 20% from 2013-2015.
Naloxone, the fast-acting opioid overdose reversal agent, represents an opportunity for pharmacists to make an impact on this public health issue. By learning practical, efficient ways to integrate naloxone dispensing services into the community pharmacy workflow, pharmacists can expand their clinical practice and potentially save lives.
Source: Centers for Disease Control and Prevention. Opioid overdose: Opioid basics, understanding the epidemic. 2017; https://www.cdc.gov/drugoverdose/epidemic/index.html
We are currently recruiting Alabama community pharmacists to participate in a study conducted by Lindsey Hohmann, PharmD, as her final dissertation project under the direction of Salisa
Westrick, PhD in the Auburn University Department of Health Outcomes Research and Policy. Community pharmacists employed in one of the following 20 counties in Alabama with the highest opioid overdose mortality rates are eligible to participate: Jefferson, Escambia, Baldwin, Walker, Blount, Mobile, Shelby, Madison, St. Clair, Cullman, Cleburne, Bibb, Marshall, DeKalb, Lawrence, Franklin, Etowah, Calhoun, Cherokee, and Morgan Counties. You do not currently have to stock or dispense naloxone in order to participate.
The goal of this study is to increase Alabama community pharmacists’ awareness, knowledge, confidence, and intentions in dispensing naloxone using evidence-based strategies to set up or streamline naloxone services in their pharmacies.
If you decide to participate in this research study, you will be randomly assigned to either an intervention or control group. Intervention group participants will immediately receive a free ACPE-accredited continuing education (CE)
program; control group participants will not immediately receive the training, but will be provided with the free CE program after the conclusion of the 3-month study.
See the FULL INFORMATION LETTER
THANK YOU TO EVERYONE WHO ENROLLED. ENROLLMENT IS NOW CLOSED!
If you are interested in participating or would like to enroll, please do so by clicking "Enroll" below:
We will then contact you to answer any questions you may have and to obtain your signed consent to participate in the research study. If you would like to review the informed consent document, you can find it here:
(Return to Lindsey Hohmann at or Fax: 334-844-8307)